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SUMMARY
Gene therapy in human disease has expanded rap-
idly in recent years with the development of safer
and more effective viral vectors, and presents a
novel approach to the treatment of epilepsy. Stud-
ies in animals models have demonstrated that
overexpression of inhibitory peptides can modify
seizure threshold, prevent the development of
epilepsy, and modify established epilepsy. More
recently there has been a flurry of studies using
optogenetics in which light-activated channels
expressed in neurons can transiently change neu-
ronal excitability on exposure to light, thereby
enabling the development of closed loop systems
to detect and stop seizure activity. The treatment
of status epilepticus presents its own challenges.
Because of both the delay in gene expression fol-
lowing transfection and also the necessity of using
focal transfection, there are a limited number of
situations in which gene therapy can be used in
status epilepticus. One such condition is epilepsia
partialis continua (EPC). We have used gene ther-
apy in a model of EPC and have shown that we can
“cure” the condition. Recent evidence suggesting
that gene therapy targeting subcortical regions
can modify generalized or more diffuse epilepsies,
indicates that the range of situations in status epi-
lepticus in which gene therapy could be used will
expand.
KEYWORDS: Epilepsia partialis continua,Animal
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The initial concept of gene therapy involved the
replacement of a defective gene, using active or inactive
viruses or virus-like particles carrying the “healthy” DNA
(Friedmann & Roblin, 1972). There are few genetic condi-
tions for which such an approach was considered suitable,
and deaths from the use of pathogenic viral vectors (in par-
ticular adenovirus) stifled early research (Romano, 2006).
In the last decade, gene therapy has undergone a resur-
gence, largely as a result of the development of effective
and safe means of transfecting cells. To date, there have
been >1,800 clinical trials approved for gene therapy
(Ginn et al., 2013), and such therapy has expanded from
replacing defective genes to overexpressing or “knocking
down” healthy genes in order to treat disease.
Gene Therapy in Epilepsy
Gene therapy in epilepsy is still in its infancy. Initial
studies overexpressing inhibitory peptides such as galanin
or neuropeptide Y (NPY) were shown to increase seizure
threshold or to modify the development of epilepsy (Ha-
berman et al., 2003; Noe et al., 2008). A decrease in gala-
nin was proposed to be a mechanism by which seizure
activity progressed to status epilepticus; administering
galanin into the hippocampus prevented such a progres-
sion from occurring (Mazarati et al., 1998). Loss of ade-
nosinergic mechanisms has also been shown to be
important for the progression to status epilepticus (Young
& Dragunow, 1994; Hamil et al., 2012). Although gene
therapy resulting in increased adenosine release has not
yet been used, a similar approach in which stem cells are
genetically engineered to release adenosine has met with
some success in treating seizures (Boison, 2009).
There is growing evidence that such approaches may
prevent the development of epilepsy and can also be used
to treat established epilepsy, but gene therapy to treat sta-
tus epilepticus brings with it particular hurdles. Foremost
among these is the time over which gene expression
occurs. Gene expression using viral vectors takes days to
weeks. This is completely at odds with the rapid time scale
over which emergency treatment of status epilepticus
takes place. Furthermore, gene therapy is usually
accomplished either ex vivo in which case cells are
modified and then placed in vivo, or by focal application
of a vector in vivo. Both of these approaches use focal
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treatment and would therefore be ideally aimed at a focal
status epilepticus. Gene therapy would ideally treat a
chronic focal status epilepticus such as epilepsia partialis
continua (EPC;Wykes et al., 2012). EPC is chronic, drug-
resistant, and usually affects eloquent cortex (Cockerell
et al., 1996), making the risks of surgery high with a high
chance of a focal deficit.
Gene Therapy in Epilepsia
Partialis Continua
We developed a rodent model of EPC by injecting
tetanus toxin into the motor cortex (Nilsen et al., 2005).
Tetanus toxin decreases neurotransmitter release and
predominantly affects inhibitory, c-aminobutyric acid
(GABA)ergic synapses. The loss of inhibition
results in focal seizure activity, which progresses over
about 3–7 days. After time, the tetanus toxin is cleared
but the seizure activity continues. Neurophysiologic
studies demonstrate that neuronal excitability increases
after injection of tetanus toxin, and this increased excit-
ability endures (Wykes et al., 2012). The clinical phe-
notype consists of tonic posturing of the limb (similar
to that observed in human EPC), but clonic movements
are not so obvious. There is a dose effect, such that at
high doses of tetanus toxin, there is marked limb postur-
ing, weight loss, and occasional sudden death associated
with a more severe seizure. Lower tetanus toxin doses
result in almost continuous electroencephalography
(EEG) seizure activity but with much subtler clinical
manifestations, and far fewer adverse effects (Wykes
et al., 2012). We continuously monitored seizure activ-
ity for weeks using a wireless transmitter sampling at
512 Hz, permitting monitoring of activity up to 160 Hz
(Chang et al., 2011).
We used three different strategies to treat this model
of status epilepticus (Wykes et al., 2012). In the first we
used an optogenetic strategy to overexpress the light-
activated chloride-pump, halorhodopsin, in pyramidal
cells. Such a strategy had been previously used in ex
vivo tissue and cell cultures (Tønnesen et al., 2009). In
that study, activating halorhodopsin reduced pyramidal
cell excitability and terminated stimulation-induced epi-
leptiform bursts and seizure-like activity induced with
the GABAA receptor antagonist picrotoxin. We extended
this method to our in vivo model of EPC. The second
strategy was to determine if permanently reducing
the excitability of a subset of pyramidal cells in the
focus during the epileptogenic process prevented the
occurrence or severity of seizures. This approach is not
so relevant to the clinical problem (i.e., treatment of
established EPC). Therefore, we pursued a third strategy
of using the same method of reducing the excitability of
a subset of pyramidal cells in the focus in previously
established epilepsy.
There are a number of different viral vectors for effi-
cient transfections of neurons (Warnock et al., 2011). Ad-
enoassociated viral vectors (AAVs) are modified adeno-
associated viruses. Adeno-associated viruses are small,
nonpathogenic, DNA viruses that insert into the genome
at a specific location. AAVs are modified so that they do
not insert but form episomes, avoiding the putative prob-
lems of insertional mutagenesis. AAVs have a predilec-
tion for neurons. Two main handicaps face AAV therapy;
the first is that AAVs can be used only to insert a limited
amount of genetic material (i.e., small genes), and the sec-
ond is that AAVs are immunogenic and their usefulness
can be restricted by the presence of neutralizing antibodies
(this is less of a problem with injection into the immune
privileged central nervous system [CNS]). There have also
been some concerns that gene expression may be time-
limited. An alternative vector is a lentivirus vector. Len-
tiviruses are retroviruses that can transfect nondividing
cells. They contain RNA, which is reversed transcribed
and inserted into the genome. Although insertional muta-
genesis is a concern, increasing numbers of studies have
revealed that the risks are vanishingly low. The lentivirus
is modified so that it is nonreplicating, and more recent
modifications render the virus self-inactivating, so that
active infection cannot take place. The advantages of len-
tivirus vectors are persistent transfection and the ability to
transfect a larger amount of DNA. Lentivirus vectors also
diffuse a shorter distance than AAVs. By selecting the
appropriate gene promoter, it is possible to restrict gene
expression to particular subsets of neurons (e.g., pyrami-
dal cells). We used lentiviral vectors to transfect predomi-
nantly pyramidal neurons with either halorhodopsin or the
potassium channel Kv1.1 (Wykes et al., 2012). We had
previously shown that Kv1.1 overexpression in neurons in
culture is an effective strategy for reducing neuronal excit-
ability. Lentiviral transfection in vivo resulted in persis-
tent gene expression for at least 6 months.
More than a week after tetanus toxin injection into the
motor cortex, when seizure activity was well established,
we were able to suppress this activity using light activa-
tion of halorhodopsin transfected into pyramidal cells in
the focus. This provides a method of regulating seizure
activity but is probably more relevant to a means of termi-
nating or preventing individual seizures using a closed
loop system. Such an approach has been used successfully
in a model of temporal lobe epilepsy by either transiently
reducing the excitability of halorhodopsin-transfected
pyramidal cells with light pulses or increasing the activity
of interneurons selectively expressing the light-activated
channel, channelrhodopsin (Krook-Magnuson et al.,
2013). Such an approach, however, is unlikely to be used
in EPC in which a continuous reduction of neuronal excit-
ability is required.
Using focal overexpression of Kv1.1, we were able to
both prevent the development of EPC and, more impor-
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tantly, stop seizure activity after it had become estab-
lished. It is important to note that our strategy reduced the
excitability of pyramidal neurons but did not interfere
with normal motor function.
Could such an approach be expanded to other forms of
refractory status epilepticus? The observations that opto-
genetic reduction of excitability of thalamic neurons using
halorhodopsin can interrupt more generalized seizure
activity (Paz et al., 2013) and that genetic manipulation of
thalamic delta GABAA receptor-subunit expression using
oligodendronucleotides can inhibit generalized spike-
wave activity (Cope et al., 2009) indicate that gene ther-
apy manipulation of subcortical structures may be an
approach that could be used to target generalized refrac-
tory status epilepticus.
Conclusion
In conclusion, we have shown how different gene
therapy approaches could be used to treat a chronic,
refractory, focal status epilepticus. At present, our meth-
ods of gene transfection mean that such approaches are
suitable only for refractory or chronic status epilepticus.
However, targeting subcortical structures may expand
the use of this treatment from very focal status epilepti-
cus to more diffuse or generalized forms of refractory
status epilepticus.
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